Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's First CRO On How ICH Affects Clinical Trials in Japan: An Interview With CMIC Exec Moriaki Akasaki

This article was originally published in The Pink Sheet Daily

Executive Summary

CMIC was established in 1992 and now is Japan's largest contract research organization, with more than 2,500 employees.

You may also be interested in...



Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview CMIC's With Moriaki Akasaki (Pt. 2)

CMIC executive discusses quality control and informed consent, and the meaning of "extravagent" trials under Japanese regulations.

Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview CMIC's With Moriaki Akasaki (Pt. 2)

CMIC executive discusses quality control and informed consent, and the meaning of "extravagent" trials under Japanese regulations.

More Than Half Of Trials Conducted In South Korea Led By Pfizer

SEOUL - The number of clinical trials Pfizer Korea conducted in South Korea last year rose sharply to 93 cases from 75 cases in 2007, a result of Pfizer's move to conduct more of its clinical trials in South Korea

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel